Design Therapeutics (DSGN) Leerink’s Global Healthcare Conference 2025 summary

Pipeline overview and strategic focus

• Advancing small molecule therapies targeting gene expression for monogenic diseases, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington's disease.

• Aiming for first-in-class or best-in-class status across all programs.

• Recently filed a 10-K and press release detailing progress.

Friedreich ataxia (DT-216P2) program updates

• Back in clinic with new DT-216P2 formulation, initially in healthy volunteers to assess safety and pharmacokinetics.

• Patient studies targeted to begin mid-2025, aiming to restore frataxin levels.

• Previous formulation showed pharmacology but had short exposure and injection site issues, addressed by new excipient in DT-216P2.

• Multiple ascending dose data expected in 2026 after 12 weeks of dosing.

• Both IV and Sub-Q routes being evaluated for long-term administration.

Clinical and preclinical insights

• Prior studies established 10 nanomolar as the target exposure for pharmacology; sustained exposure is now the goal.

• New formulation shows improved duration and tolerability in nonclinical studies.

• Frataxin protein measurement now reliable using advanced mass spectrometry.

• 12-week dosing required to reach steady-state frataxin protein levels.